Curated coverage from top medical journals and quality journalism, with our take on what it means for hormonal health, bone health, and midlife care.
60 articles
The UK government announced that menopause will be integrated into routine NHS health checks for women aged 40 to 74 — the first time the national health system has systematically screened for menopause symptoms.
The landmark SWAN longitudinal study showed that bone mineral density remains stable in early perimenopause but declines sharply in late perimenopause — about 2% per year — continuing into early postmenopause.
Research on digital biomarker monitoring shows that longitudinal tracking of health data can identify high-risk individuals years before clinical diagnosis, enabling targeted prevention for type 2 diabetes, cardiovascular disease, and other chronic conditions.
The landmark FREEDOM trial published in NEJM showed that denosumab, a monoclonal antibody, significantly reduced vertebral, hip, and nonvertebral fractures in women with osteoporosis over 3 years.
A large-scale analysis finds that more than half of women aged 40-64 experience perimenopause or menopause symptoms, yet only 8% receive a confirmed diagnosis — exposing a systemic recognition gap in clinical care.
A Mayo Clinic study finds menopause symptoms cost $1.8 billion annually in lost work time and $26.6 billion when medical expenses are added, with 13% of working women reporting at least one adverse work outcome due to symptoms.
Rock Health's annual Digital Health Consumer Adoption Survey finds wearable health device ownership has jumped 10 points since 2019, with 86% of patients reporting improved health outcomes from wearable technology.
A comprehensive review documents the growing osteoporosis treatment gap — with diagnosis rates below 20% and post-fracture treatment rates declining despite effective therapies being available.
New research details how cortisol, melatonin, testosterone, and thyroid hormones follow precise circadian patterns, with disruption linked to metabolic disease, mood disorders, and accelerated aging.
A population-based study finds that sex hormone-binding globulin independently predicts cardiovascular and metabolic risk, with low SHBG increasing diabetes risk up to tenfold and changing differently with age in men versus women.
The U.S. Preventive Services Task Force reaffirmed screening for women 65+ and expanded guidance on risk assessment for younger postmenopausal women.
A clinical review finds obesity increases hypogonadism risk up to 8.7-fold, while low testosterone promotes further fat accumulation, creating a self-reinforcing metabolic trap that requires integrated monitoring to break.
A study in JAMA Internal Medicine found that hip fractures in healthy older women are associated with sharply increased short-term mortality — underscoring the urgency of fracture prevention.
The USPSTF's Grade A and B recommendations cover depression, diabetes, hypertension, and cancer screening for adults, yet most Americans do not follow the recommended schedule, missing early detection opportunities.
A retrospective study combining NHANES and claims data reveals that 4-7% of community-derived populations have undiagnosed hypothyroidism, with higher prevalence in women, older adults, and certain ethnic groups.
A meta-analysis of 27 clinical trials found that men receiving testosterone treatment were 130% more likely to see significant improvement in depressive symptoms, even in some men with normal testosterone levels.
A landmark study from the Manitoba BMD Registry demonstrated that trabecular bone score — a measure of bone microarchitecture — predicts fractures independently of traditional bone density measurements.
A review in Menopause reveals that despite affecting 40-56% of peri- and postmenopausal women, sleep disturbance associated with menopause has no specifically approved pharmacological treatment.
The Endocrine Society's updated 2024 guideline reframes vitamin D as a hormone the kidneys produce, recommending empiric supplementation for adults over 75, pregnant women, and those with prediabetes.
A systematic review of 11 RCTs found that exercise training had a negligible effect on resting testosterone in insufficiently active men, challenging the popular narrative that working out reliably boosts T levels.
An updated review in Endocrine details how chronic glucocorticoid use causes rapid bone loss — up to 12% in the first year — and fractures in 30-50% of long-term users.
A state-by-state analysis reveals that only Illinois and Louisiana require insurance providers to cover menopause treatment, leaving millions of women navigating inconsistent coverage and out-of-pocket costs of $20-500 per month.
Research shows sperm volume and motility decline after age 35, with DNA fragmentation increasing from the late 20s. Men over 45 face a fivefold longer time to pregnancy.
A comprehensive JAMA review revisits the Women's Health Initiative 30 years after launch, clarifying what the landmark trial actually found and what it means for clinical practice today.
A comprehensive review highlights that male osteoporosis affects 1-2 million U.S. men, yet up to 95% of men with hip fractures are discharged without osteoporosis treatment.
A comprehensive review examines 15 years of FRAX validation data, showing its strengths in predicting 10-year fracture probability and its known limitations.
Research reveals that estrogen's complex pro- and anti-inflammatory effects, combined with X-chromosome gene dosage, explain the striking 4:1 female-to-male ratio in autoimmune disease.
The Lancet's landmark 2024 menopause series challenges the idea that menopause universally increases depression and anxiety risk, identifying specific subgroups most vulnerable to psychological distress.
The TRAVERSE trial correspondence in NEJM clarifies a decade of conflicting cardiovascular signals around testosterone therapy, confirming no increased MACE risk while flagging arrhythmia signals that demand monitoring.
A comprehensive JAMA meta-analysis found that vitamin D alone does not reduce fracture risk, but daily combined vitamin D and calcium supplementation reduced hip fractures by 16%.
Research links low testosterone with obesity and metabolic syndrome, showing how excess insulin drives testosterone suppression in men and androgen excess in women, creating a metabolic-hormonal feedback loop.
A policy perspective from the Endocrine Society finds that endocrinology is well-suited to telehealth because most hormonal management relies on labs and patient history rather than physical examination, though clinician adoption concerns persist.
A comprehensive review examines the distinct health trajectories of women who experience menopause before 40 or 45, including elevated risks for cardiovascular disease, osteoporosis, and type 2 diabetes.
Nearly 25% of men over 50 will suffer an osteoporotic fracture, yet fewer than 6% receive bone density screening. The Lancet calls male osteoporosis one of medicine's most overlooked conditions.
A randomized controlled trial showed that brief, supervised high-intensity resistance training improved lumbar spine BMD by nearly 3% in postmenopausal women with low bone mass.
ACOG's 2023 clinical consensus statement addresses the gap between marketing claims and evidence for compounded bioidentical hormone therapy, urging caution and calling for rigorous trials.
Research shows hormones actively regulate DNA methylation patterns, and age-related hormonal decline triggers epigenetic changes that may accelerate biological aging beyond chronological age.
AHRQ's SHARE approach and supporting research demonstrate that patients who engage in shared decision-making experience decreased anxiety, faster recovery, and increased treatment adherence.
A meta-analysis of 18 studies involving 1,823 men found a significant inverse association between obstructive sleep apnea and serum testosterone, independent of BMI and age.
A JAMA Internal Medicine meta-analysis of 10 RCTs found that bisphosphonates need about 12 months to prevent a nonvertebral fracture and 20 months for a hip fracture.
A systematic review finds that allostatic load, the cumulative burden of chronic stress, increases with age and predicts cardiovascular disease, cognitive decline, and earlier mortality.
The landmark SCOOP trial demonstrated that systematic screening of older women using FRAX risk assessment led to a 28% reduction in hip fractures compared to usual care.
The landmark TRAVERSE trial of 5,246 men found that testosterone replacement therapy was noninferior to placebo for major cardiovascular events, resolving a decade-long safety debate.
A clinical review examines the evidence for SSRIs and SNRIs as non-hormonal alternatives for menopausal hot flashes, finding 50-60% reduction in frequency versus 80-90% with estrogen therapy.
WHO projects the global population aged 60+ will reach 1.4 billion by 2030 and 2.1 billion by 2050, with two-thirds living in low- and middle-income countries, creating an unprecedented demand for hormonal and chronic disease management.
A Danish cohort study published in Scientific Reports finds that long-term mortality among hormone therapy users was not elevated — and that the healthiest users appear to have stopped therapy after the WHI scare, skewing post-2002 safety data.
A comprehensive review reveals the gut microbiome actively metabolizes sex hormones through enzyme secretion, with dysbiosis linked to altered estrogen and testosterone levels and associated disease states.
The FDA approved fezolinetant (Veozah), a non-hormonal NK3 receptor antagonist, for moderate to severe hot flashes — the first drug engineered from the ground up for menopausal vasomotor symptoms.
The Endocrine Society's 2018 guidelines require both persistent symptoms and two confirmed low morning testosterone readings before diagnosis, raising the standard for evidence-based hormonal care.
A foundational NEJM study demonstrated that estrogen therapy preserves bone density in postmenopausal women — establishing the hormonal link that still drives clinical decisions today.
A landmark Mayo Clinic study quantifies the economic toll of menopause symptoms on working women: $1.8 billion in lost productivity and $26.6 billion when medical expenses are included.
The UK Parliament's inquiry into menopause and the workplace found that only 26% of UK companies offer formal menopause policies, despite evidence showing an 80% boost in staff retention when adjustments are provided.
A Frontiers review details the epidemiology, physiology, and diagnostic gaps surrounding genitourinary syndrome of menopause — a progressive condition that worsens without treatment and remains widely under-reported.
A landmark NHANES-based study estimates 10.2 million Americans have osteoporosis and another 43.4 million have low bone mass — more than half of all adults over 50.
A Circulation review argues that the cardiovascular effects of hormone therapy depend heavily on when treatment begins relative to menopause — supporting a critical window for safe initiation.
A Lancet review of studies since 2016 links BPA and phthalate exposure to diabetes, reduced semen quality, PCOS, and obesity, calling for urgent policy action to reduce endocrine-disrupting chemical exposure.
A systematic review and meta-analysis of 26 RCTs and 47 observational studies finds that menopausal hormone therapy's cardiovascular effects vary significantly by age, formulation, and timing of initiation.
The Baltimore Longitudinal Study of Aging found that testosterone declines at a consistent rate with age, with hypogonadal levels reaching 20% of men over 60 and 50% over 80.
A clinical review in Climacteric maps the science behind menopause-related cognitive symptoms, from verbal memory deficits to measurable gray matter changes, and offers guidance for clinicians counseling patients on brain fog.
A 25-year review of SWAN study data reveals that Black women experience more severe hot flashes, higher rates of hypertension and depression during menopause, and are less likely to receive treatment for any of these conditions.
Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.